Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.82
NYSE:BMY's Cash to Debt is ranked lower than
61% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NYSE:BMY: 0.82 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BMY' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.81 Max: 2.26
Current: 0.82
0.32
2.26
Equity to Asset 0.46
NYSE:BMY's Equity to Asset is ranked lower than
73% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:BMY: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BMY' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.45 Max: 0.55
Current: 0.46
0.33
0.55
Interest Coverage 20.88
NYSE:BMY's Interest Coverage is ranked lower than
65% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. NYSE:BMY: 20.88 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BMY' s Interest Coverage Range Over the Past 10 Years
Min: 4.67  Med: 14.09 Max: 45.84
Current: 20.88
4.67
45.84
F-Score: 5
Z-Score: 5.63
M-Score: -2.04
WACC vs ROIC
8.54%
15.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 19.21
NYSE:BMY's Operating margin (%) is ranked higher than
79% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. NYSE:BMY: 19.21 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BMY' s Operating margin (%) Range Over the Past 10 Years
Min: 11.41  Med: 18.21 Max: 31.29
Current: 19.21
11.41
31.29
Net-margin (%) 18.22
NYSE:BMY's Net-margin (%) is ranked higher than
84% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:BMY: 18.22 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BMY' s Net-margin (%) Range Over the Past 10 Years
Min: 9.19  Med: 14.13 Max: 56.42
Current: 18.22
9.19
56.42
ROE (%) 22.66
NYSE:BMY's ROE (%) is ranked higher than
88% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. NYSE:BMY: 22.66 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BMY' s ROE (%) Range Over the Past 10 Years
Min: 10.75  Med: 19.06 Max: 78.36
Current: 22.66
10.75
78.36
ROA (%) 10.39
NYSE:BMY's ROA (%) is ranked higher than
80% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NYSE:BMY: 10.39 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BMY' s ROA (%) Range Over the Past 10 Years
Min: 4.78  Med: 7.63 Max: 35.08
Current: 10.39
4.78
35.08
ROC (Joel Greenblatt) (%) 97.64
NYSE:BMY's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.88 vs. NYSE:BMY: 97.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BMY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 45.71  Med: 56.78 Max: 155.17
Current: 97.64
45.71
155.17
Revenue Growth (3Y)(%) -1.90
NYSE:BMY's Revenue Growth (3Y)(%) is ranked lower than
71% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:BMY: -1.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BMY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.4  Med: 2.3 Max: 11.8
Current: -1.9
-8.4
11.8
EBITDA Growth (3Y)(%) -6.10
NYSE:BMY's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. NYSE:BMY: -6.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:BMY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -26  Med: -2.4 Max: 21.5
Current: -6.1
-26
21.5
EPS Growth (3Y)(%) -7.10
NYSE:BMY's EPS Growth (3Y)(%) is ranked lower than
68% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:BMY: -7.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:BMY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: -4.8 Max: 30.7
Current: -7.1
-22.9
30.7
» NYSE:BMY's 10-Y Financials

Financials (Next Earnings Date: 2017-04-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BMY Guru Trades in Q4 2015

Tom Gayner 10,000 sh (New)
Louis Moore Bacon 260,000 sh (New)
John Burbank 1,958,072 sh (+387.99%)
Ray Dalio 70,845 sh (+262.79%)
Pioneer Investments 215,566 sh (+147.85%)
Ken Fisher 134,800 sh (+120.33%)
Steven Cohen 1,264,200 sh (+15.03%)
Vanguard Health Care Fund 46,232,449 sh (+1.95%)
Mairs and Power 287,063 sh (+0.87%)
Ronald Muhlenkamp 211,755 sh (unchged)
Jeremy Grantham 5,400 sh (unchged)
Steven Cohen 117,500 sh (unchged)
Steven Cohen 117,500 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Samuel Isaly 1,333,000 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
RS Investment Management 521,050 sh (-0.31%)
Murray Stahl 57,542 sh (-1.54%)
Mario Gabelli 639,355 sh (-1.85%)
Jeff Auxier 4,943 sh (-1.98%)
Kahn Brothers 28,050 sh (-2.60%)
First Eagle Investment 12,943 sh (-2.87%)
Dodge & Cox 77,458 sh (-3.09%)
T Rowe Price Equity Income Fund 4,520,000 sh (-18.01%)
Paul Tudor Jones 10,400 sh (-36.27%)
» More
Q1 2016

BMY Guru Trades in Q1 2016

Ron Baron 112,848 sh (New)
Ken Fisher 636,060 sh (+371.85%)
Ray Dalio 86,845 sh (+22.58%)
Paul Tudor Jones 11,800 sh (+13.46%)
Pioneer Investments 233,487 sh (+8.31%)
Vanguard Health Care Fund 47,754,809 sh (+3.29%)
Murray Stahl 58,876 sh (+2.32%)
Mario Gabelli 654,005 sh (+2.29%)
Kahn Brothers 28,583 sh (+1.90%)
Jeff Auxier 4,993 sh (+1.01%)
RS Investment Management 526,000 sh (+0.95%)
Ronald Muhlenkamp 212,200 sh (+0.21%)
First Eagle Investment 12,943 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Louis Moore Bacon Sold Out
Ruane Cunniff Sold Out
Mairs and Power 285,918 sh (-0.40%)
Signature Select Canadian Fund 250,300 sh (-3.21%)
Dodge & Cox 73,458 sh (-5.16%)
T Rowe Price Equity Income Fund 4,031,100 sh (-10.82%)
Jeremy Grantham 4,100 sh (-24.07%)
John Burbank 1,374,032 sh (-29.83%)
Steven Cohen 532,100 sh (-57.91%)
Samuel Isaly 1,029,700 sh (-22.75%)
» More
Q2 2016

BMY Guru Trades in Q2 2016

Keeley Asset Management Corp 2,960 sh (New)
Jim Simons 537,000 sh (New)
Ray Dalio 186,454 sh (+114.70%)
Paul Tudor Jones 13,800 sh (+16.95%)
Ken Fisher 648,107 sh (+1.89%)
Ron Baron 114,941 sh (+1.85%)
Samuel Isaly 1,108,400 sh (+7.64%)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 4,993 sh (unchged)
John Burbank Sold Out
Mairs and Power 285,748 sh (-0.06%)
Murray Stahl 58,776 sh (-0.17%)
Dodge & Cox 72,158 sh (-1.77%)
Vanguard Health Care Fund 45,257,309 sh (-5.23%)
Mario Gabelli 619,627 sh (-5.26%)
Jeremy Grantham 3,800 sh (-7.32%)
First Eagle Investment 11,529 sh (-10.92%)
Steven Cohen 470,600 sh (-11.56%)
Ronald Muhlenkamp 181,340 sh (-14.54%)
Pioneer Investments 199,079 sh (-14.74%)
T Rowe Price Equity Income Fund 3,325,000 sh (-17.52%)
RS Investment Management 366,010 sh (-30.42%)
» More
Q3 2016

BMY Guru Trades in Q3 2016

Julian Robertson 400,800 sh (New)
Joel Greenblatt 87,321 sh (New)
Jim Simons 4,740,200 sh (+782.72%)
Paul Tudor Jones 116,887 sh (+747.01%)
Ray Dalio 390,577 sh (+109.48%)
Mairs and Power 330,822 sh (+15.77%)
Vanguard Health Care Fund 48,804,797 sh (+7.84%)
Ken Fisher 650,332 sh (+0.34%)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
First Eagle Investment 11,529 sh (unchged)
Jeremy Grantham Sold Out
Keeley Asset Management Corp Sold Out
Steven Cohen Sold Out
Dodge & Cox 71,958 sh (-0.28%)
Ronald Muhlenkamp 180,316 sh (-0.56%)
Murray Stahl 56,324 sh (-4.17%)
Jeff Auxier 4,693 sh (-6.01%)
T Rowe Price Equity Income Fund 3,100,000 sh (-6.77%)
Mario Gabelli 556,927 sh (-10.12%)
Pioneer Investments 110,604 sh (-44.44%)
Ron Baron 47,479 sh (-58.69%)
Samuel Isaly 955,887 sh (-13.76%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP913.130.22$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:GLAXF, NYSE:ABBV, NYSE:SNY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, NYSE:NVS, OTCPK:OTSKF, NYSE:MRK, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH, OTCPK:MAYNF, NAS:HCM » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Bristol-Myers Squibb Co is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products.

Bristol-Myers Squibb Co is a Delaware corporation and was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called 'biologics'. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others. The Company promotes its products to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The Company's products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in six foreign countries. The markets in which the Company competes are generally broad-based and competitive. The Company competes with other research-based drug companies, research companies and generic drug manufacturers. The Company is subject to regulation by regional, country, state and local agencies.

Ratios

vs
industry
vs
history
P/E(ttm) 28.58
BMY's P/E(ttm) is ranked lower than
51% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. BMY: 28.58 )
Ranked among companies with meaningful P/E(ttm) only.
BMY' s P/E(ttm) Range Over the Past 10 Years
Min: 4.09  Med: 22.01 Max: 77.61
Current: 28.58
4.09
77.61
Forward P/E 18.38
BMY's Forward P/E is ranked lower than
63% of the 63 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. BMY: 18.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.58
BMY's PE(NRI) is ranked lower than
51% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.46 vs. BMY: 28.58 )
Ranked among companies with meaningful PE(NRI) only.
BMY' s PE(NRI) Range Over the Past 10 Years
Min: 12.33  Med: 23.68 Max: 77.61
Current: 28.58
12.33
77.61
Price/Owner Earnings (ttm) 70.19
BMY's Price/Owner Earnings (ttm) is ranked lower than
77% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.53 vs. BMY: 70.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BMY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.57  Med: 27.32 Max: 987.29
Current: 70.19
3.57
987.29
P/B 6.13
BMY's P/B is ranked lower than
80% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. BMY: 6.13 )
Ranked among companies with meaningful P/B only.
BMY' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 4.19 Max: 8.51
Current: 6.13
2.46
8.51
P/S 5.19
BMY's P/S is ranked lower than
68% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. BMY: 5.19 )
Ranked among companies with meaningful P/S only.
BMY' s P/S Range Over the Past 10 Years
Min: 1.63  Med: 2.85 Max: 7.24
Current: 5.19
1.63
7.24
PFCF 106.29
BMY's PFCF is ranked lower than
87% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. BMY: 106.29 )
Ranked among companies with meaningful PFCF only.
BMY' s PFCF Range Over the Past 10 Years
Min: 7.45  Med: 19.79 Max: 926.83
Current: 106.29
7.45
926.83
POCF 47.24
BMY's POCF is ranked lower than
84% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. BMY: 47.24 )
Ranked among companies with meaningful POCF only.
BMY' s POCF Range Over the Past 10 Years
Min: 6.96  Med: 14.75 Max: 147.61
Current: 47.24
6.96
147.61
EV-to-EBIT 21.12
BMY's EV-to-EBIT is ranked higher than
50% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.07 vs. BMY: 21.12 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 12.95 Max: 126.7
Current: 21.12
6.2
126.7
EV-to-EBITDA 19.73
BMY's EV-to-EBITDA is ranked lower than
56% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.70 vs. BMY: 19.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 10.55 Max: 57.3
Current: 19.73
5.5
57.3
Shiller P/E 26.63
BMY's Shiller P/E is ranked higher than
74% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.94 vs. BMY: 26.63 )
Ranked among companies with meaningful Shiller P/E only.
BMY' s Shiller P/E Range Over the Past 10 Years
Min: 10.83  Med: 16.72 Max: 36.19
Current: 26.63
10.83
36.19
Current Ratio 1.47
BMY's Current Ratio is ranked lower than
72% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BMY: 1.47 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.61 Max: 2.32
Current: 1.47
1.13
2.32
Quick Ratio 1.30
BMY's Quick Ratio is ranked lower than
64% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. BMY: 1.30 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.34 Max: 2.07
Current: 1.3
0.93
2.07
Days Inventory 106.81
BMY's Days Inventory is ranked higher than
54% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.28 vs. BMY: 106.81 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 124.57 Max: 141.93
Current: 106.81
84.37
141.93
Days Sales Outstanding 75.35
BMY's Days Sales Outstanding is ranked higher than
51% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.78 vs. BMY: 75.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.65 Max: 79.99
Current: 75.35
35.38
79.99
Days Payable 113.74
BMY's Days Payable is ranked higher than
73% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.88 vs. BMY: 113.74 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 78.8  Med: 141.65 Max: 230.86
Current: 113.74
78.8
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.66
BMY's Dividend Yield is ranked higher than
70% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 2.66 )
Ranked among companies with meaningful Dividend Yield only.
BMY' s Dividend Yield Range Over the Past 10 Years
Min: 1.99  Med: 4.1 Max: 7.07
Current: 2.66
1.99
7.07
Dividend Payout 0.76
BMY's Dividend Payout is ranked lower than
82% of the 386 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. BMY: 0.76 )
Ranked among companies with meaningful Dividend Payout only.
BMY' s Dividend Payout Range Over the Past 10 Years
Min: 0.41  Med: 0.68 Max: 37
Current: 0.76
0.41
37
Dividend Growth (3y) 2.80
BMY's Dividend Growth (3y) is ranked lower than
62% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.00 vs. BMY: 2.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BMY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.1 Max: 11.4
Current: 2.8
0
11.4
Forward Dividend Yield 2.75
BMY's Forward Dividend Yield is ranked higher than
67% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. BMY: 2.75 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.07
BMY's Yield on cost (5-Year) is ranked higher than
65% of the 791 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. BMY: 3.07 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BMY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.3  Med: 4.73 Max: 8.16
Current: 3.07
2.3
8.16
3-Year Average Share Buyback Ratio -0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 435 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. BMY: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: -0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.93
BMY's Price/Tangible Book is ranked lower than
89% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. BMY: 12.93 )
Ranked among companies with meaningful Price/Tangible Book only.
BMY' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.91  Med: 13.84 Max: 53.46
Current: 12.93
4.91
53.46
Price/Projected FCF 2.20
BMY's Price/Projected FCF is ranked higher than
58% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. BMY: 2.20 )
Ranked among companies with meaningful Price/Projected FCF only.
BMY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.59 Max: 4.53
Current: 2.2
1.15
4.53
Price/Median PS Value 1.82
BMY's Price/Median PS Value is ranked lower than
77% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. BMY: 1.82 )
Ranked among companies with meaningful Price/Median PS Value only.
BMY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.68  Med: 1.13 Max: 3.01
Current: 1.82
0.68
3.01
Price/Graham Number 4.05
BMY's Price/Graham Number is ranked lower than
77% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. BMY: 4.05 )
Ranked among companies with meaningful Price/Graham Number only.
BMY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.75  Med: 4.09 Max: 15.06
Current: 4.05
1.75
15.06
Earnings Yield (Greenblatt) (%) 4.72
BMY's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. BMY: 4.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 7.7 Max: 16.1
Current: 4.72
0.8
16.1
Forward Rate of Return (Yacktman) (%) -7.00
BMY's Forward Rate of Return (Yacktman) (%) is ranked lower than
80% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.15 vs. BMY: -7.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BMY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.1  Med: 4.5 Max: 26.7
Current: -7
-15.1
26.7

More Statistics

Revenue (TTM) (Mil) $18,471
EPS (TTM) $ 2.00
Beta0.89
Short Percentage of Float0.90%
52-Week Range $49.03 - 77.12
Shares Outstanding (Mil)1,671.23

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 19,230 20,171 21,084 20,816
EPS ($) 2.76 3.00 3.30 3.34
EPS w/o NRI ($) 2.76 3.00 3.30 3.34
EPS Growth Rate
(3Y to 5Y Estimate)
21.06%
Dividends Per Share ($) 1.66 1.74 1.61
» More Articles for NYSE:BMY

Headlines

Articles On GuruFocus.com
Early Hedge Funder Julian Robertson Buys 2 Positions in 3rd Quarter Nov 14 2016 
52-Week Company Lows Nov 03 2016 
Baron Funds Comments on Bristol-Myers Squibb Co. Oct 25 2016 
52-Week Company Lows Oct 21 2016 
The Time Is Right to Pick Up Bristol-Myers Squibb Oct 17 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
52-Week Company Lows Oct 07 2016 
Take a Look at Sanofi Oct 05 2016 
52-Week Company Lows Sep 29 2016 
52-Week Company Lows Sep 22 2016 

More From Other Websites
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017 Dec 09 2016
Bristol-Myers Declares 39-Cent Cash Dividend Dec 09 2016
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs Dec 09 2016
Bristol-Myers Squibb settles with Mass., other states over Abilify marketing Dec 08 2016
Official: Bristol-Myers Squibb to pay to settle allegations Dec 08 2016
Official: Bristol-Myers Squibb to pay to settle allegations Dec 08 2016
4:16 pm Bristol-Myers increases quarterly dividend to $0.39/share from $0.38/share Dec 08 2016
Bristol-Myers Squibb Announces Dividend Increase Dec 08 2016
Bristol-Myers Squibb to pay $19.5 mln to settle off-label promotion case Dec 08 2016
Bristol-Meyers Squibb to pay $19.5 mln to settle off-label promotion case Dec 08 2016
EU clears Bristol-Myers immunotherapy drug for blood cancer Dec 06 2016
Bristol-Myers Reports Data from Opdivo Combination Studies Dec 06 2016
Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and... Dec 06 2016
Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating... Dec 05 2016
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell Dec 05 2016
D E Shaw Makes Massive Investments in Apple, Disney, More Dec 05 2016
Assessing Bristol-Myers Stock Valuation (BMY) Dec 05 2016
Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up... Dec 05 2016
Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up... Dec 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)